CareersPipelineCollaboration RareInnovation SVGOMG The best SVG optimizer and minifier Open SVG Paste markup Demo Contribute SVGOMG provides you several options to clean and compress your SVG files. Clean up, remove, merge, minify. Upload or copy the source of your SVG to get started! 947 bytes → 267 bytes 28.19% Finance peopleAdvance treatment Skip to main contentSkip to navigationSkip to search
HNSA   ( ,  %) SEK
Quotes are delayed 15 minutes

With our clinical and preclinical research programs we evaluate imlifidase and HNSA-5487 across a spectrum of both potential disease areas and indications.

Imlifidase HNSA-5487
Preclinical
Phase 1
Phase 2
Phase 3
Marketing authorization
Marketed
Status

Imlifidase

Desensitization in gene therapy: Limb-Girdle Muscular Dystrophy

Partnered with Sarepta Therapeutics

Preclinical research ongoing

Focus areas Regulatory status

Sponsored research

We believe it is important to support ethical independent clinical research conducted by qualified third-party investigators (investigator sponsored trials or ISTs). Investigators are encouraged to submit study concepts to Hansa Biopharma.

Investigators can reach out to one of our medical science liaisons (MSL) or alternatively email the Company’s Investigator Sponsored Trial Review Committee at [email protected].

Interested in being part of a clinical trial?

If you are a patient and interested in participating in one of Hansa’s clinical trials or studies, please talk to your physician. 

Compassionate use

Hansa is committed to leveraging our unique immunomodulating technology platform to develop innovative, lifesaving, and life-altering treatments for patients with rare immunologic conditions. As we take our commitment to patients very seriously, Hansa shares your urgency as we strive to develop new treatments and complete the rigorous scientific and regulatory requirements. We firmly believe that conducting thorough clinical trials to evaluate safety and efficacy, and securing regulatory approval, is paramount to ensuring that our treatments reach as many patients as possible.

As a result, we are unable to offer a compassionate use program at this time without jeopardizing our ability to conduct the trials needed to gain timely regulatory approval and provide patients broad, equitable, and sustainable access. We believe the most appropriate way to access our investigational therapies is to participate in clinical trials assessed by regulatory entities across the globe.  Completing our current and future clinical trials, with diligence and efficiency, remains the best path to potential regulatory approval and ensuring widespread access to our therapies.

Hansa will continue to evaluate the possibility of compassionate use and will update our policy if our position changes. Physicians seeking more information can contact [email protected]. We anticipate acknowledging receipt of requests within 5 business days.  For information regarding Hansa clinical trials, please visit:

clinicaltrials.gov